Compare KRYS & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRYS | CYTK |
|---|---|---|
| Founded | 2015 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2B | 7.8B |
| IPO Year | 2017 | 2004 |
| Metric | KRYS | CYTK |
|---|---|---|
| Price | $305.25 | $56.14 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 22 |
| Target Price | ★ $388.22 | $109.42 |
| AVG Volume (30 Days) | 296.5K | ★ 1.9M |
| Earning Date | 11-02-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 128.00 | N/A |
| EPS | ★ 5.66 | N/A |
| Revenue | ★ $389,130,000.00 | $13,368,000.00 |
| Revenue This Year | $27.84 | $87.17 |
| Revenue Next Year | $27.62 | $170.90 |
| P/E Ratio | $54.71 | ★ N/A |
| Revenue Growth | ★ 33.94 | N/A |
| 52 Week Low | $198.02 | $53.58 |
| 52 Week High | $382.54 | $88.31 |
| Indicator | KRYS | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 43.87 | 38.83 |
| Support Level | $284.16 | N/A |
| Resistance Level | $317.53 | $66.62 |
| Average True Range (ATR) | 11.47 | 2.68 |
| MACD | 0.01 | -0.27 |
| Stochastic Oscillator | 49.77 | 25.69 |
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.